In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $34.09, marking a +2.13% move from the previous day ...

Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is ...

Viking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase. VKTX's dual-track pipeline (injectable and oral) and robust $700M liquidity position it ...

Viking Therapeutics, Inc. (VKTX) reached $31.86 at the closing of the latest trading day, reflecting a -7.21% change compared ...

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries ...

By Puyaan Singh Jan 12 (Reuters) - Weight-loss drug developer Viking Therapeutics CEO said on Monday that strategic interest ...

Viking Therapeutics recently completed patient enrollment in an exploratory maintenance dosing study of VK2735, its dual ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Viking Therapeutics Inc (Symbol: VKTX), where a total volume of 27,860 contracts ...